Divi's Laboratories Limited — Q3 FY26 earnings call

Call held 11 Feb 2026

Management summary

Divi's Laboratories reported a robust Q3 FY26, with consolidated total income growing to ₹2,692 crores and pre-exceptional profit before tax increasing to ₹854 crores, driven by improved operating performance and a favorable product mix. The company saw healthy volume traction in generics, active engagement in custom synthesis, and continued growth in nutraceuticals. Operational efficiencies and a successful FDA inspection underscored strong quality, though competitive pricing in generics and potential raw material cost pressures from China's policy changes remain areas of vigilance.

Highlights

  • Consolidated total income for Q3 FY26 was ₹2,692 crores, up 12.12% YoY from ₹2,401 crores.

  • Profit before exceptional item and tax for Q3 FY26 stood at ₹854 crores, up 17.63% YoY from ₹726 crores.

  • Material consumption as a percentage of sales revenue improved to 36.3% in Q3 FY26 from 39.8% in Q3 FY25.

  • Nutraceutical segment contributed ₹214 crores to revenue in Q3 FY26, demonstrating healthy performance.

  • Successfully concluded a U.S. FDA general CGMP inspection at Unit 1 Choutuppal facility, reaffirming quality standards.

Concerns

  • The pricing environment in the Generics segment remains competitive.

  • China's withdrawal of export tax rebates on certain products may lead to selective pricing pressures on raw materials over time.

  • A one-time incremental impact of ₹74 crores was recorded relating to employee benefit obligations due to new labor codes.

Key financials

  1. Consolidated Total Income ₹2,692 Cr +12.1%YoY
  2. Profit before exceptional item and tax ₹854 Cr +17.6%YoY
  3. Profit after tax ₹583 Cr -1%YoY
  4. Material consumption % of sales 36.3%
  5. Nutraceutical segment revenue ₹214 Cr
  6. Foreign exchange gain ₹19 Cr

What they filed

Q1 FY27: revenue up 26.2%, net profit up 60.0% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue2,302 2,297 2,536 2,357 2,660 +16%2,578 +12%2,793 +10%2,974 +26%
EBITDA729 747 881 743 895 +23%907 +21%943 +7%1,240 +67%
Net profit518 594 667 557 696 +34%598 +1%756 +13%891 +60%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • Generics
    43% Product Mix Share
  • Custom Synthesis
    57% Product Mix Share
  • Nutraceuticals
    ₹214 Cr Revenue (Q3 FY26)₹706 Cr Revenue (9M FY26)22.6% Revenue Growth (9M FY26 YoY)

Capital allocation

high confidence
  • Capex ₹313 Cr this quarter · ₹1,900 Cr (FY26) planned
    • Ongoing capacity expansion and backward integration initiatives
    For the 9-month period ended December 31, 2025, capitalized assets of ₹313 crores during the quarter and ₹776 crores for the 9 months period. Capital work in progress stood at 2,394 crores as of December 31, 2025, in line with our ongoing capacity expansion and backward integration initiatives. [...] So we did intimate that we are doing a capex of ₹1900 crores to SEBI in the last many months.
  • Liquidity Cash ₹3,686 Cr
    As of December 31, 2025, we had cash and cash equivalents of ₹3,686 crores, receivables of ₹2,637 crores and inventories of ₹3,667 crores.

Guidance & targets

Commercialization

  • Custom Synthesis Projects Commercial Volumes Commercialization · Q3/Q4 2027 · Medium confidence Starting Q3/Q4 2027
    So we are assuming depending on all regulatory approvals happening on time, somewhere in Q3, Q4 of 2027 is when the commercial volumes will start moving.

    — Dr. Kiran S. Divi

Capex

  • FY26 Capex Capex · FY26 · High confidence ₹1900 crores
    So we did intimate that we are doing a capex of ₹1900 crores to SEBI in the last many months.

    — Nilima Prasad Divi

Efficiency

  • Asset Turnover Ratio Efficiency · Next 4-5 years · Medium confidence 1.5 to 1.6
    can it go back to the historical high level of 1.5 to 1.8 level in next 4, 5 years? How should we understand the going forward, the revenue trajectory? [...] So based on the forward-looking statements and a few clarifications that Dr. Kiran Divi has provided, we can say that's what we are aiming at and that's what we are trying to go towards.

    — Harshit Dhoot (question), Nilima Prasad Divi (response)

Market context

  • Constant Currency Growth Growth · Ongoing · Medium confidence Double-digit
    To be yes, we do not foresee any disruption because and it's in line with whatever our double-digit growth that we keep talking about.

    — Nilima Prasad Divi

What to watch in Q4 FY26

GLP-1 Validation Progress

Next quarter / within 6 months
Current Pilot plant and one commercial building completed, validations ongoing.
Target Completion of validations and movement towards regulatory clearances.

Why it matters

Key indicator for future commercialization of high-value peptide products.

validations are going on as we speak right now because pilot work is done, now it's moving towards validations.

Risks & concerns

  • Competitive Pricing Environment in Generics

    medium

    The pricing environment for generic products remains competitive, impacting value realization despite healthy volume traction.

    Management acknowledged

  • Impact of China's Export Tax Rebates Withdrawal

    medium

    China's withdrawal of export tax rebates on certain products, effective April 1, may lead to selective pricing pressures on raw materials, though Divi's is diversifying its vendor base.

    Management acknowledged

  • Regulatory Approvals for New Products

    medium

    Commercialization of new products, especially in Custom Synthesis, is contingent on completing validations and obtaining regulatory approvals from customers and agencies, which can be time-consuming.

    Management acknowledged

  • One-time Employee Benefit Obligation Impact

    low

    A one-time incremental impact of ₹74 crores was recorded due to revisions in employee benefit obligations following new labor codes.

    Management acknowledged

Q&A highlights

3 direct, 4 evasive
GLP-1 Capacity Build-up Evasive
So I'm not at the liberty to speak about capacity created, but the validations are going on as we speak right now because pilot work is done, now it's moving towards validations.

Analyst sought specific capacity details for GLP-1, a high-interest area, but management cited confidentiality.

Asked by Surya Narayan Patra

Nature of 3 Dedicated Custom Synthesis Facilities Evasive
I cannot comment on that, but what I can tell you is it's a mixture of everything. It's also in chemistry. There are several projects which are involved in it.

Analyst probed if new CS facilities were peptide-related, but management maintained confidentiality on product specifics.

Asked by Surya Narayan Patra

Hedging Policy for Exports Direct
We are not hedging. We are evaluating at this point based on the overall scenario in the market.

Management clarified their current stance on hedging, indicating exposure to currency fluctuations while evaluating options.

Asked by Tushar Manudhane

Growth in Generic Space Partial
See, the generic space, the pricing pressures are still continuing. We haven't mentioned that the pricing have eased. We did mention that the pricing pressures are still continuing. But if we look at generics, we need to see one is the value and another is the volume. As a volume, we have had a good growth. But it's just that because of the pricing pressure, value-wise, it doesn't reflect in that manner.

Analyst questioned subdued generic growth despite stable raw materials, and management attributed it to persistent pricing pressures impacting value, despite volume growth.

Asked by Tushar Manudhane

Impact of New CS Products on Margins Evasive
I would say that's all we hope for. As our Managing Director would say 'the sky is the limit for you to dream'.

Analyst sought specific financial impact of new CS commercializations on margins, but management gave an aspirational, non-committal response.

Asked by Vivek Agrawal

China's Export Tax Rebates Withdrawal Impact Direct
I didn't mention that with respect to the APIs. I said with respect to procurement of materials. So the withdrawal of export tax rebates has taken place and will be from effect from April 1. We are wary of the situation that's there. But we are also like from the last many years, we've been trying to diversify as much as possible from China.

Management clarified the specific impact of China's policy change on raw material procurement, not APIs, and highlighted their mitigation strategy.

Asked by Neha Manpuria

Unit 3's Role in Backward Integration and Commercialization Direct
So if I could explain this better, Unit 1 and Unit 2 in the past were making their own pre-chemistry and backward integrated raw materials. And once Unit 3 started, phase-wise, we have been emptying Unit 1 and 2 as and when there is demand, where the blocks get empty, and we are using them for all the new projects by modifying them.

Management provided strategic clarity on how Unit 3 supports existing units and enables new project development.

Asked by Neha Manpuria

GLP-1 Manufacturing Process Changes Evasive
It's hard for me to comment on what you asked. But what I can say is we're actively involved in manufacturing fragments for several MNCs. We're also involved in their new technologies, whatever they are looking at, and we are actively engaged with them at various phases because we are also their support system going forward, both at LPPS and at SPPS.

Analyst inquired about Divi's involvement in cost-reduction changes for GLP-1 manufacturing, but management gave a general response about their role with MNCs without specifics.

Asked by Girish Bakhru

2 min read 6 chapters

Detailed narrative

Q3 FY26 Financial Performance Overview

Divi's Laboratories reported a consolidated total income of ₹2,692 crores for Q3 FY26, marking a 12.12% year-over-year increase from ₹2,401 crores. Profit before exceptional items and tax rose by 17.63% YoY to ₹854 crores, compared to ₹726 crores in the prior year. However, profit after tax saw a slight decline of 1.02% YoY to ₹583 crores. The company also recorded a foreign exchange gain of ₹19 crores during the quarter.

Generics and Custom Synthesis Segment Performance

The Generics segment maintained stable performance, supported by strong backward integration and process efficiencies, despite a competitive pricing environment. Generics constituted 43% of the product mix in Q3 FY26. The Custom Synthesis segment, representing 57% of the product mix, is actively engaged in multiple RFPs and customer visits, with several projects progressing towards commercial volumes within the next year, with some expected to start moving in Q3/Q4 2027.

Nutraceuticals and Peptide Segment Growth

The Nutraceuticals segment delivered a healthy performance, contributing ₹214 crores to the Q3 FY26 revenue. For the nine-month period, nutraceutical revenue reached ₹706 crores, a 22.57% YoY growth from ₹576 crores. This year marks 20 years for Divi's Nutraceuticals, with ongoing capacity expansion. In the Peptide segment, Divi's continues to advance work in complex building blocks and fragments, supporting multiple customer programs across all clinical phases, leveraging decades of experience in protected amino acids.

Manufacturing and Unit 3 Strategy

Unit 3 at Kakinada is playing a crucial role in Divi's backward integration strategy, with operational blocks effectively used for starting materials and intermediates, strengthening the supply chain. Expansions and transfer activities are progressing as planned, with additional manufacturing blocks being developed. This strategy aims to free up capacity at Units 1 and 2 for new projects. The company also successfully concluded a U.S. FDA general CGMP inspection at its Unit 1 Choutuppal facility, reaffirming its commitment to quality and regulatory compliance.

Operational Efficiency and Risk Management

Operational efficiency improved, with material consumption as a percentage of sales revenue decreasing to 36.3% in Q3 FY26 from 39.8% YoY. Divi's is expanding its technology platforms, including process automation and new chemistry platforms, to enhance efficiency, improve process safety, and strengthen overall production. While raw material prices were broadly stable, management remains vigilant regarding potential pricing pressures from China's withdrawal of export tax rebates and continues to diversify its vendor base to mitigate supply risks.

Capital Expenditure and Future Outlook

Capitalized assets amounted to ₹313 crores in Q3 FY26, contributing to ₹776 crores for the nine-month period. Capital work in progress stood at ₹2,394 crores as of December 31, 2025, in line with ongoing capacity expansion and backward integration initiatives. The targeted capex for FY26 is ₹1,900 crores. The company aims to improve its asset turnover ratio to a range of 1.5 to 1.6 in the next 4-5 years, indicating efficient utilization of its growing asset base and a focus on long-term value creation.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls